---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-000026"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2022-01-04T23:59:59+00:00"
generated_at: "2026-06-27T20:50:03.906622+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics expands credit facility to $200M, extends maturity to 2026

## Summary
- Loan increased from $60M to $200M; initial $70M drawn, $7.8M used to refinance existing balance.
- Maturity extended to Jan 1, 2026; interest-only period extended to Feb 1, 2025 (extendable to Aug 1, 2025).
- Interest rate: prime + 2.15% (floor 5.40%); warrants issued for 115,042 shares at $17.95, 7-year term.
- Financial covenants: minimum cash from Oct 15, 2022; market cap/cash covenants from July 1, 2023 if drawn >$70M.

## SEC filing metadata
- accession: 0001558370-22-000026
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2022-01-04T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837022000026/0001558370-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837022000026/tgtx-20211230x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-000026
- JSON: https://secwatch.observer/filing/0001558370-22-000026.json
- Plain text: https://secwatch.observer/filing/0001558370-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.